Organigram Reports Second Quarter Fiscal 2026 Results
Organigram reported Q2 Fiscal 2026 net revenue of $59.8 million, a 9% decrease from the prior year, driven by lower vape and infused pre-roll sales. Adjusted EBITDA was $0.9 million, down 82% from $4.9 million in Q2 Fiscal 2025, primarily due to lower recreational revenue and higher returns provisions. The company completed the acquisition of Sanity Group, a leading German cannabis company, subsequent to quarter-end. Sanity Group is expected to generate approximately €25 million in average quarterly revenue over the next calendar year.
Key figures
- Revenue
- 59794000
- Guidance
- Fiscal 2026 net revenue to exceed $350 million, Adjusted EBITDA and Adjusted Gross Margin to exceed Fiscal 2025 performance, Free Cash Flow approximately break even, capital expenditures of less than $10 million
- Revenue Yoy
- -9%
- Thc potency
- highest average THC potency across the Company's flagship Moncton facility
- Sga expenses
- 23609000
- Total assets
- 521312000
- Gross revenue
- 93250000
- Harvest yield
- 32,000 kg
- Adjusted ebitda
- 870000
- Total liabilities
- 149500000
- Shareholders equity
- 371812000
- Adjusted gross margin
- 18441000
- International revenue
- 6100000
- Adjusted gross margin percentage
- 31%
- Net cash used in operating activities
- 6760000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.